Anuh PharmaBOM:506260 -0.51%86 Interest Coverage is 159.55 as of Mar. 2026, which is 7% above its 10-year median of 148.97. GuruFocus rates BOM:506260 with a GF Score™ of 86/100 and a GF Value™ of ₹105.70 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 687 Drug Manufacturers companies, Anuh Pharma ranks better than 78.75% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Anuh Pharma's
Operating Income
for the
three
months ended in Mar. 2026 was ₹169 Mil. Anuh Pharma's Interest Expense for the
three
months ended in Mar. 2026 was ₹-1 Mil.
Anuh Pharma's interest coverage for the quarter that ended in Mar. 2026 was 159.55.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Anuh Pharma Ltd has enough cash to cover all of its debt. Its financial situation is stable.
The historical rank and industry rank for Anuh Pharma's Interest Coverage or its related term are showing as below:
BOM:506260'
s Interest Coverage Range Over the Past 10 Years
Min: 20.39 Med: 148.97 Max: 587.75
Current: 100.51
BOM:506260's Interest Coverage is ranked better than 78.75% of 687
companies
in the Drug Manufacturers industry
Industry Median: 12.75
vs BOM:506260: 100.51
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Anuh Pharma Interest Coverage Related Terms
Anuh Pharma Interest Coverage Historical Data
* Premium members only.
The historical data trend for Anuh Pharma's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
BOM:506260 vs ZTS, UTHR: Interest Coverage Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Anuh Pharma's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anuh Pharma Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Anuh Pharma's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Anuh Pharma's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anuh Pharma (BOM:506260) has a Interest Coverage of 159.55 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Anuh Pharma and its competitors. This is near median its historical median of 148.97. Over the past decade, Anuh Pharma's Interest Coverage has ranged from 20.39 to 587.75. According to the industry distribution chart, Anuh Pharma ranks #146 out of 687 companies in the Drug Manufacturers industry, placing it in the top 21.3%.
Is Anuh Pharma's Interest Coverage too high?
Anuh Pharma's current Interest Coverage of 159.55 is near median its 10-year median of 148.97. Over the past 10 years, this metric has ranged from a low of 20.39 to a high of 587.75. The Drug Manufacturers industry median Interest Coverage is 12.75. Anuh Pharma's value of 159.55 is 1151.4% above this industry median. Based on the distribution chart, Anuh Pharma ranks #146 out of 687 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Anuh Pharma has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Anuh Pharma's Interest Coverage compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Anuh Pharma ranks #146 out of 687 companies for Interest Coverage. This places Anuh Pharma in the top 21% of its industry — outperforming the majority of peers. The industry median Interest Coverage is 12.75. Anuh Pharma's value of 159.55 is 1151.4% above this benchmark. Historically, Anuh Pharma's own Interest Coverage has ranged from 20.39 to 587.75 over the past decade. While the company's 10-year median is 148.97 vs. the industry median of 12.75, Anuh Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.75, based on 687 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Anuh Pharma's current Interest Coverage of 159.55 is 1151.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Anuh Pharma and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anuh Pharma's current Interest Coverage is 159.55, which is near median its own 10-year median of 148.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anuh Pharma stock overvalued right now?
Based on GuruFocus' analysis, Anuh Pharma (BOM:506260) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹105.70, compared to a current price of ₹78.73 — trading 25.5% below its estimated fair value. The current Interest Coverage is 159.55, which is near median its 10-year median of 148.97 and 1151.4% above the Drug Manufacturers industry median of 12.75. Anuh Pharma's overall GF Score™ is 86/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Anuh Pharma (BOM:506260), the current Interest Coverage is 159.55 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Anuh Pharma (BOM:506260) Overvalued in 2026?
Based on GuruFocus' analysis, Anuh Pharma stock appears to be undervalued.
The current stock price of ₹78.73 is trading 25.5% below its estimated GF Value™ of ₹105.70.
GuruFocus considers Anuh Pharma to be Modestly Undervalued.
Key valuation signals for BOM:506260:
Interest Coverage: 159.55 (near median its 10-year median of 148.97)
GF Value™: ₹105.70 vs. price of ₹78.73 (25.5% below fair value)
Industry Position: 1151.4% above the Drug Manufacturers median (#146 of 687)
No single metric tells the full story. See the BOM:506260 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Anuh Pharma Ltd is engaged in the business of manufacturing and selling of Bulk drugs and chemicals. Geographically, it derives a majority of revenue from India. Its product categories include macrolides, anti-TB, anti-malarial, anti-bacterial, anti-hypertension, expectorant, quinolones, and others. The company generates revenue from the sale of Branded Prescription drugs, Over-the-Counter (OTC) drugs and Generic Prescription drugs.
86GF Score
Get the complete analysis for BOM:506260
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:506260 has been successfully added to your 
